Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Agarwal Website

Piyush K. Agarwal, M.D.

Selected Publications

1)  Weintraub MD, Li QQ, Agarwal PK.
Advances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (Review).
Mol Clin Oncol. 2: 656-660, 2014.
[Journal]
2)  Ahmed K, Khan SA, Hayn MH, Agarwal PK, Badani KK, Balbay MD, Castle EP, Dasgupta P, Ghavamian R, Guru KA, Hemal AK, Hollenbeck BK, Kibel AS, Menon M, Mottrie A, Nepple K, Pattaras JG, Peabody JO, Poulakis V, Pruthi RS, Redorta JP, Rha KH, Richstone L, Saar M, Scherr DS, Siemer S, Stoeckle M, Wallen EM, Weizer AZ, Wiklund P, Wilson T, Woods M, Khan MS.
Analysis of intracorporeal compared with extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.
Eur. Urol. 65: 340-7, 2014.
[Journal]
3)  Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kevin Kelly W, Agarwal PK, Koppie TM, Kaag MG, Quinn DI, Vogelzang NJ, Sridhar SS.
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States.
Urol. Oncol. 32: 637-44, 2014.
[Journal]
4)  Park JC, Citrin DE, Agarwal PK, Apolo AB.
Multimodal management of muscle-invasive bladder cancer.
Curr Probl Cancer. 38: 80-108, 2014.
[Journal]
5)  Nakrani RN, Ghosh A, Richard Lee C, Agarwal PK, Apolo AB, Cowen EW.
New facial papules in a 66-year-old woman with bladder cancer.
J. Am. Acad. Dermatol. [Epub ahead of print], 2014.
[Journal]
6)  Ghosh M, Brancato SJ, Agarwal PK, Apolo AB.
Targeted therapies in urothelial carcinoma.
Curr Opin Oncol. 26: 305-20, 2014.
[Journal]
7)  Hoang AN, Agarwal PK, Walton-Diaz A, Wood CG, Metwalli AR, Kassouf W, Brown GA, Black PC, Urbauer DL, Grossman HB, Dinney CP, Kamat AM.
Clinical Significance of Ureteral 'Skip Lesions' at the Time of Radical Cystectomy: the Md-Anderson Experience and Review of Literature.
BJU Int. [Epub ahead of print], 2013.
[Journal]
8)  Johar RS, Hayn MH, Stegemann AP, Ahmed K, Agarwal P, Balbay MD, Hemal A, Kibel AS, Muhletaler F, Nepple K, Pattaras JG, Peabody JO, Palou Redorta J, Rha K, Richstone L, Saar M, Schanne F, Scherr DS, Siemer S, Stökle M, Weizer A, Wiklund P, Wilson T, Woods M, Yuh B, Guru KA.
Complications After Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
Eur. Urol. 64: 52-7, 2013.
[Journal]
9)  Kheterpal E, Sammon JD, Diaz M, Bhandari A, Trinh Q, Pokala N, Sharma P, Menon M, Agarwal PK.
Effect of metabolic syndrome on pathologic features of prostate cancer.
Urol. Oncol. 31: 1054-9, 2013.
[Journal]
10)  Marshall SJ, Hayn MH, Stegemann AP, Agarwal PK, Badani KK, Balbay MD, Dasgupta P, Hemal AK, Hollenbeck BK, Kibel AS, Menon M, Mottrie A, Nepple K, Pattaras JG, Peabody JO, Poulakis V, Pruthi RS, Palou Redorta J, Rha K, Richstone L, Schanne F, Scherr DS, Siemer S, Stöckle M, Wallen EM, Weizer AZ, Wiklund P, Wilson T, Woods M, Guru KA.
Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC).
BJU Int. 111: 1075-80, 2013.
[Journal]
11)  Vourganti S, Harbin A, Singer EA, Shuch B, Metwalli AR, Agarwal PK.
Low Grade Micropapillary Urothelial Carcinoma, Does It Exist? - Analysis of Management and Outcomes from the Surveillance, Epidemiology and End Results (SEER) Database.
J Cancer. 4: 336-42, 2013.
[Journal]
12)  Guru KA, Peabody JO, Ahmed K, Kibel A, Weizer A, Hayn M, Johar R, Agarwal P, Balbay M, Hemal A, Muhletaler F, Nepple K, Pattaras J, Redorta J, Rha K, Richstone L, Saar M, Schanne F, Scherr D, Siemer S, Stoekle M, Wilson T, Woods M, Yuh B, Wiklund P.
Reply from Authors re: Manfred P. Wirth, Johannes Huber. What Really Matters Is Rarely Measured: Outcome of Routine Care and Patient-reported Outcomes. Robot-assisted Versus Open Radical Cystectomy: Beating a Dead Horse.
Eur. Urol. 64: 60-1, 2013.
[Journal]
13)  Li QQ, Wang G, Liang H, Li JM, Huang F, Agarwal PK, Zhong Y, Reed E.
ß-Elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas.
Anticancer Res. 33: 1421-8, 2013.
[Journal]
14)  Trinh Q, Sun M, Kim SP, Sammon J, Kowalczyk KJ, Friedman AA, Sukumar S, Ravi P, Muhletaler F, Agarwal PK, Shariat SF, Hu JC, Menon M, Karakiewicz PI.
The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy.
Urol. Oncol. 32: 29.e13-20, 2013.
[Journal]
15)  Trinh Q, Sun M, Sammon J, Bianchi M, Sukumar S, Ghani KR, Jeong W, Dabaja A, Shariat SF, Perrotte P, Agarwal PK, Rogers CG, Peabody JO, Menon M, Karakiewicz PI.
Disparities in access to care at high-volume institutions for uro-oncologic procedures.
Cancer. 118: 4421-6, 2012.
[Journal]
16)  Trinh Q, Sun M, Sammon J, Tian Z, Bianchi M, Shariat SF, Jeong W, Ghani KR, Jeldres C, Perrotte P, Agarwal PK, Rogers CG, Peabody JO, Menon M, Karakiewicz PI.
Leapfrog volume thresholds and perioperative complications after radical prostatectomy.
Cancer. 118: 4991-8, 2012.
[Journal]
17)  Agarwal PK.
Editorial comment.
J. Urol. 185: 1261, 2011.
[Journal]
18)  Fujisue Y, Azuma H, Inamoto T, Komura K, Agarwal PK, Masuda H, Watsuji T, Katsuoaka Y.
Neoadjuvant hormonal therapy does not impact the treatment success of high-intensity focused ultrasound for the treatment of localized prostate cancer.
World J Urol. 29: 689-94, 2011.
[Journal]
19)  Agarwal PK, Sammon J, Bhandari A, Dabaja A, Diaz M, Dusik-Fenton S, Satyanarayana R, Simone A, Trinh QD, Baize B, Menon M.
Safety profile of robot-assisted radical prostatectomy: a standardized report of complications in 3317 patients.
Eur. Urol. 59: 684-98, 2011.
[Journal]
20)  Black PC, Shetty A, Brown GA, Esparza-Coss E, Metwalli AR, Agarwal PK, McConkey DJ, Hazle JD, Dinney CP.
Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis.
BJU Int. 106: 1799-804, 2010.
[Journal]
21)  Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke A, Pisters LL, Swanson DA, Dinney CP, Kamat AM.
Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy.
Urology. 73: 147-52, 2009.
[Journal]
22)  Agarwal PK, Black PC, Kamat AM.
Considerations on the use of diagnostic markers in management of patients with bladder cancer.
World J Urol. 26: 39-44, 2008.
[Journal]
23)  Kassouf W, Agarwal PK, Herr HW, Munsell MF, Spiess PE, Brown GA, Pisters L, Grossman HB, Dinney CP, Kamat AM.
Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC.
J. Clin. Oncol. 26: 121-6, 2008.
[Journal]
24)  Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR.
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes.
Cancer. 112: 307-14, 2008.
[Journal]
25)  Agarwal PK, Black PC, McConkey DJ, Dinney CP.
Emerging drugs for targeted therapy of bladder cancer.
Expert Opin Emerg Drugs. 12: 435-48, 2007.
[Journal]
26)  Black PC, Agarwal PK, Dinney CP.
Targeted therapies in bladder cancer--an update.
Urol. Oncol. 25: 433-8, 2007.
[Journal]
27)  Agarwal PK, Oefelein MG.
Testosterone replacement therapy after primary treatment for prostate cancer.
J. Urol. 173: 533-6, 2005.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 8/21/2014.